Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ayala Pharmaceuticals Inc ADXS

Healthcare Biotechnology
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The Company's lead candidate is aspacytarabine (BST-236), a novel anti-metabolite for first line treatment in unfit acute myeloid leukemia... see more

Recent & Breaking News (PINL:ADXS)

Advaxis to Present at the Cantor Fitzgerald Global Healthcare Conference

Business Wire September 25, 2018

Advaxis Announces Closing of Its Public Offering of Common Stock and Warrants

Business Wire September 11, 2018

Advaxis Reports Fiscal 2018 Third Quarter Business Highlights and Financial Results

Business Wire September 10, 2018

Advaxis Announces Pricing of Its Public Offering of Common Stock and Warrants

Business Wire September 7, 2018

Advaxis, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Warrants

Business Wire September 6, 2018

Advaxis Licenses ADXS-HER2 to OS Therapies for Evaluation in the Treatment of Osteosarcoma

Business Wire September 4, 2018

Advaxis Announces FDA Allowance of IND Application for ADXS-HOT Drug Candidate for Non-Small Cell Lung Cancer

Business Wire July 30, 2018

Advaxis Announces FDA Lifts Clinical Hold on Phase 1/2 Combination Study of Axalimogene Filolisbac with Durvalumab

Business Wire July 13, 2018

Advaxis Provides Update on MAA Filing and ADXS-HOT Program

Business Wire July 10, 2018

Advaxis Announces Dosing of First Patient with ADXS-NEO, an Investigational Customized Immunotherapy Approach Targeting Personal Neoantigens

Business Wire June 11, 2018

Advaxis Announces Prioritization of Product Portfolio and Reports Fiscal 2018 Second Quarter Financial Results

Business Wire June 7, 2018

Advaxis Appoints Molly Henderson as Chief Financial Officer

Business Wire June 6, 2018

Data Highlighting Advaxis’ ADXS-PSA Presented at ASCO Annual Meeting

Business Wire June 1, 2018

Advaxis to Host Business Update and Second Quarter 2018 Financial Results Conference Call on June 7, 2018

Business Wire May 31, 2018

Analysis: Positioning to Benefit within Advaxis, e.l.f. Beauty, Heron Therapeutics, PVH, Energy Recovery, and A. O. Smith — Research Highlights Growth, Revenue, and Consolidated Results

GlobeNewswire May 14, 2018

Recently Presented Preclinical Data Show Potential for ADXS-NEO as Anti-Cancer Immunotherapy Agent

Business Wire May 11, 2018

Advaxis Announces Executive Leadership Changes

Business Wire April 23, 2018

Preclinical Data Highlighting ADXS-Hot as Immunotherapy with Potential to Target Hotspot Cancer Mutations across Multiple Cancer Types Presented in Poster Discussion at The AACR Annual Meeting

Business Wire April 17, 2018

Data Highlighting Advaxis’ ADXS-PSA Accepted as Poster Presentation at the American Society of Clinical Oncology Annual Meeting

Business Wire April 2, 2018

Advaxis Announces Four Poster Presentations Highlighting Lm-based Antigen Delivery Technology at AACR 2018

Business Wire March 26, 2018